CG Inbites, Merger by Absorption of Makaon Biotherapeutics
CG Inbites announced on the 11th that it will absorb and merge with Makaon Biotherapeutics.
Hot Picks Today
"Parents Deposited 10 Million Won for Me"... Se...
- "SK Hynix Stock Windfall"... Teenager With Wads of Cash Turns Thief at Jewelry S...
- Trump Meets with Oil Industry Executives: "Blockade Against Iran Could Last for ...
- "Major Crash Is Coming... Buy Even If You Have to Skip a Meal" 'Rich Dad' Shares...
- "Save 30 Million Won, Grow It to 100 Million": Dramatic Pledge Sparks "Is This a...
The purpose of the merger is to increase management efficiency and maximize synergy through the merger, and the form of the merger is a small-scale merger. Makaon Biotherapeutics' main business is pharmaceutical research and development.
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
